Replies to post #114718 on Biotech Values

[DewDiligence]

Maybe when they say, "We continue to model an April 1 Teva launch, " that just means exactly that, they model it, but are not assuming a 100% probability of that outcome.

I don’t think they are applying a probably weighting in this instance, but the more basic criticism of the report is that FDA approval of Teva’s Lovenox by 4/1/11 is quite impossible. The only reason I can see for using such a date for modeling purposes is to mislead.